You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Background and Objectives<br />
• ABT-494 is a novel selective JAK-1 inhibitor<br />
– It is under development for the treatment of moderate to severe RA<br />
• Two Phase 2b studies aimed to compare the efficacy and safety of<br />
various doses of ABT-494 against placebo in RA patients receiving a<br />
stable dose of MTX<br />
– One study included patients with an inadequate response to MTX 1<br />
– The other included patients with an inadequate response to or<br />
intolerance of 1 anti-TNF agent 2<br />
1. <strong>Genovese</strong> MC, et al. Arthritis Rheum 2016;68:2857–66.<br />
2. <strong>Kremer</strong> JM, et al. Arthritis Rheum 2016;68:2867–77.
Change language